Tags » Hemophilia A

Researchers find way to reverse clotting factor deficiency that triggers hemophilia A

For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases

Sufferers of hemophilia live in a perpetual state of stress and anxiety: their joints wear down prematurely and they have bleeding episodes that feel like they will never end.  426 more words

NEWS

Hemophilia therapies drive outpatient pharmacy costs for publicly insured children

Swenson SM, et al. JAMA. 2015;doi:10.1001/jama.2015.7169.

July 29, 2015  From: HemOncToday

Medications for the treatment of hemophilia are a considerable driver of outpatient pharmacy expenditures for publicly insured children with serious chronic conditions, according to study results. 428 more words

Hemophilia

Researchers find way to reverse clotting factor deficiency that triggers hemophilia A

Published on July 24, 2015 at 7:10 AM  from News-Medical.net

For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases… 461 more words

Hemophilia

Ethanol locks reduce central venous catheter-associated bloodstream infections in children with cancer

Hemophilia patients with a port-a-cath typically use Heparin to “lock” at the end of the infusion.  The following article give an alternative to Heparin for patients with bloodstream infections. 536 more words

Hemophilia

U.S. FDA Accepts for Review CSL Behring’s Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A

rVIII-SingleChain underscores CSL Behring’s deep commitment to developing and delivering specialty biotherapies that improve the well-being of patients with serious diseases

KING OF PRUSSIA, Pa. — 28 July 2015… 655 more words

Hemophilia

Alnylam Reports New Positive Clinical Data for ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders

06.23.2015

– New Interim Data from Ongoing Phase 1 Study in Hemophilia Subjects Demonstrate an up to 86% AT Knockdown and a Re-Balancing of Hemostasis with Normalization of Thrombin Generation up to a Mean Increase of 350% and Marked Improvements in Whole Blood Clotting – 3,505 more words

Hemophilia

Roche announces further encouraging data from study of ACE910 in adults and adolescents with severe haemophilia A

23 June 2015 from Roche Investor Update

  • Data from Phase I extension study presented at major medical conference on bleeding disorders showed that reduction in bleeding rates was maintained after a follow-up of 5.6 to 18.5 months…
  • 1,091 more words
Hemophilia